Targeting Adenosine A2b Receptor Promotes Penile Rehabilitation of Refractory Erectile Dysfunction
Overview
Affiliations
The mechanisms of adenosine and specific adenosine receptor subtypes in promoting penile rehabilitation remain unclear. Single-cell RNA sequencing of human corpus cavernosum, adenosine deaminase (ADA) and adenosine receptors knock-out mice (ADA, A1, A2a, A2b, and A3), and primary corpus cavernosum smooth muscle cells are used to determine receptor subtypes responsible for adenosine-induced erection. Three rat models are established to characterize refractory erectile dysfunction (ED): age-related ED, bilateral cavernous nerve crush related ED (BCNC), and diabetes mellitus-induced ED. In single-cell RNA sequencing data, the corpus cavernosum of ED patients show a decrease in adenosine A1, A2a and A2b receptors. In vivo, A2b receptor knock-out abolishes adenosine-induced erection but not that of A1, A2a, or A3 receptor. Under hypoxic conditions in vitro, activating the A2b receptor increases HIF-1α and decreases PDE5 expression. In refractory ED models, activating the A2b receptor with Bay 60-6583 improves erectile function and down-regulates HIF-1α and TGF-β. Administering Dipyridamole (40 mg Kg) to BCNC rats improve penile adenosine levels and erectile function. Our study reveals that the A2b receptor mediates adenosine-induced penile erection. Activating the A2b receptor promotes penile rehabilitation of refractory ED by alleviating hypoxia and fibrosis.
Adenosine signaling: a potential therapeutic target for psychogenic erectile dysfunction.
Xue K, Yan M, Zhu Z, Cui J Am J Transl Res. 2025; 16(12):7248-7261.
PMID: 39822506 PMC: 11733318. DOI: 10.62347/YZDZ1428.
Yang W, Fang J, Zhai J, Qiu C, Liang Z, Liu Q BMC Med. 2024; 22(1):376.
PMID: 39256772 PMC: 11389314. DOI: 10.1186/s12916-024-03609-3.
Targeting Adenosine A2b Receptor Promotes Penile Rehabilitation of Refractory Erectile Dysfunction.
Xiong Y, Qin F, Wei S, Yang X, Li J, Wu C Adv Sci (Weinh). 2024; 11(30):e2306514.
PMID: 38874549 PMC: 11321695. DOI: 10.1002/advs.202306514.